logo-loader
viewAvacta Group PLC

Avacta's revenues and cash ahead of expectation as it prepares to take its first drug candidate into the clinic

The company is the developer of antibody-like proteins called Affimers

Avacta Group PLC -

Avacta Group PLC (LON:AVCT) shares rose on Thursday as the firm said revenues and cash were ahead of forecast and the life sciences specialist reconfirmed plans to take its first drug into the clinic later this year.

The developer of antibody-like proteins called Affimers said it had benefited from collaborations with companies such as LG Chem and ADC Therapeutics, which funded its R&D activities.

READ: Avacta creates cell therapy JV with Korea's Daewoong Pharmaceutical

And it expects to receive a boost this year from the recently-signed tie-up with Daewoong Pharmaceuticals.

Avacta’s trading statement covered the 17 months ended December 31 and showed revenues had doubled to £5.5mln. It ended the period with cash of £8.7mln after successfully completing a share placing last November.

The company’s protein-scaffold platform has potential applications in the life sciences research, diagnostics and therapeutics.

These Affimers are capable of binding specific molecular targets, in a similar way to antibodies.

This binding property can be used to target cancer cells in the human body and make those cells vulnerable to attack from the body’s own immune system.

In the middle of next year, Avacta will take AVA6000, its most advanced drug candidate, into the clinic with the read-out from the early-phase trial expected by the end of 2020.

AVA6000 is essentially a re-engineered form of the chemotherapy Doxorubicin modified using the company’s pre | CISION technology to reduce the side effects without diminishing the efficacy.

Avacta believes the headline results from the study could provide a major inflection point and a “significant commercial opportunity”.

In a note to clients, analysts at ‘house’ broker finnCap called Avacta’s trading update “positive”, and reiterated a target price of 76p on the stock.

In morning trading, Avacta shares added 2.4% at 18.50p.

 -- Adds analyst comment, share price --

Quick facts: Avacta Group PLC

Price: 20.5 GBX

AIM:AVCT
Market: AIM
Market Cap: £36.09 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 opens in red ahead of US job numbers; Bail-out for...

Headlines from the Proactive UK newsroom. London’s leading shares are set to open on the back foot this morning ahead of the release later of US jobs figures for March.. But economists say the full scale of the rising jobless in the US economy will be revealed in next month’s...

18 hours, 27 minutes ago

2 min read